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Abstract
Background: There is a scarcity of studies addressing the factors associated with impaired fasting
glucose in Chinese patients with uncomplicated hypertension. We included 1,218 patients newly
prescribed a single antihypertensive drug in the public primary healthcare setting in Hong Kong,
where their fasting glucose levels were measured 6–7 weeks after the first-ever antihypertensive
prescription.
Methods: The odds ratios of having above borderline (≥ 6.1 mmol/l) and adverse (≥ 7.0 mmol/l)
glucose levels, respectively, were studied according to patient age, gender, socioeconomic status,
clinic types and antihypertensive drug classes by multivariable regression analyses.
Results: The fasting glucose levels were statistically similar (p = 0.786) among patients prescribed
thiazide diuretics (5.48 mmol/l, 95%, 5.38, 5.59), calcium channel blockers (5.46 mmol/l, 95% C.I.
5.37, 5.54), β-blockers (5.42 mmol/l, 95% C.I. 5.34, 5.51) and drugs acting on the renin angiotensin
system (RAS) [5.41 mmol/l, 95% C.I. 5.20, 5.61]. Multivariate analyses reported no significant
associations between antihypertensive drug class and impaired fasting glucose. Elderly patients and
male gender were significantly more likely to present with above borderline and adverse readings
respectively.
Conclusion: Clinicians should be aware of the increased risk of impaired fasting glucose in these
groups, and use of thiazides should not in itself deter its use as a first-line antihypertensive agent
among ethnic Chinese patients.
Background
Hypertension was estimated to be present in at least 73%
of citizens in the United States who have diabetes [1].
Many people were diagnosed with hypertension prior to
diabetes [2], and a significant number of hypertensive
patients have diabetes gone unrecognized [3]. Diabetes
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was reported to impose a two-fold or greater risk for car-
diovascular morbidity and mortality [4] and together with
hypertension this risk increased dramatically [5]. The co-
existence of diabetes and hypertension are associated with
greater degrees of arterial stiffness [6] which leads to ear-
lier rises in systolic and pulse pressures [7].
The importance of early detection of diabetes among
hypertensive patients has been highlighted in the guide-
lines of the American Diabetes Association [8] and the
seventh report of the Joint National Committee [9], which
called for screening for diabetes at the time of diagnosing
hypertension and repeating screening annually.
There has been evidence that thiazide diuretics could pre-
cipitate overt diabetes [10] and it was well recognized in
authoritative medical textbooks [11] that diuretics are
"contraindications" in prescribing for maturity-onset dia-
betic patients. However, recent debate arose as to the best
first-line antihypertensive in diabetic patients. For
instance, diuretics were labeled as the least expensive and
most effective agent, and "... should be the first line treat-
ment almost everyone with hypertension, including
patients with diabetes..." [12]. In addition, studies on the
relationship between antihypertensive drug classes and
hyperglycemia among ethnic Chinese patients were
scarce. Local surveys among Chinese doctors reported that
the majority chose thiazide diuretics as the best first-line
agent for patients newly diagnosed with uncomplicated
hypertension [13] but most changed their choice to Angi-
otensin Converting Enzyme inhibitors when diabetes was
co-existing [14] due to physicians' concerns that impaired
fasting glucose could be a significant side effect of thiazide
diuretics. To our knowledge there have been no studies
evaluating the association of various antihypertensive
drug classes with the development of impaired fasting glu-
cose or diabetes among ethnic Chinese patients.
The present study examined the factors associated with
elevated fasting glucose in Chinese patients with uncom-
plicated hypertension newly prescribed a single antihy-
pertensive prescription.
Methods
Data source
The Clinical Data Analysis and Reporting System
(CDARS) of the Hospital Authority, Hong Kong consists
of all patient records in public, primary health sector visits
since 2000. It captures patients' demographics, clinical
information including diagnoses, prescription details and
laboratory investigation results in every out-patient con-
sultation. One of the major functions of CDARS is
research [15]. It is the single portal of information entry
for all physicians practicing in the public sector in Hong
Kong, and is a comprehensive record which allows cross-
referencing when patients visit a different clinic in the
public health sector. Also, it is the policy of all public clin-
ics in Hong Kong to have their drug prescription details
doubly checked by pharmacist professionals and any
amendments were also recorded in the electronic patient
record. In addition to these good practices this database
has been evaluated and found a high level of complete-
ness with respect to demographic data (100%) and pre-
scription details (99.98%) [16]. The present study
included populations residing in the New Territory East
Cluster (NTEC) of Hong Kong, which has a population of
around 1.3 million. This cluster is further divided into 3
separate regions, namely Shatin, Tai-Po and the North
District, from the most urbanized to the most rural
regions respectively. Their median monthly household
incomes in 2006 were US$2,510, US$2,338 and
US$2,078 for these three regions respectively, compared
to the Hong Kong-wide figure of US$2,240. These three
regions have similar median ages (38–39 years), compa-
rable with the median age of 39 years for Hong Kong [17].
This study gained approval from the Survey and Behav-
ioural Research Ethics Committee, Chinese University of
Hong Kong.
Subjects
Patients newly attended the public primary care practice,
coded by physicians with International Classification of
Primary Care (ICPC) K86 [uncomplicated hypertension]
and who were prescribed at least one antihypertensive
agent as the first-ever antihypertensive pharmacotherapy
in the public sector during the study period of January
2004 to June 2007 were included. Only patients who had
their fasting glucose levels checked 4 to 16 weeks after the
first-ever antihypertensive prescription were included.
Exclusion criteria included subjects having concomitant
cardiovascular factors or clinical conditions which could
confound the prescription choice of antihypertensive
drugs, identified by the respective ICPC codes as follows:
complicated hypertension (K87), diabetes mellitus (T90),
impaired glucose tolerance (T91), gout (T92), lipid disor-
der (T93), stroke and cerebrovascular accident (K90 and
K91), ischemic heart diseases (K74, K76), acute myocar-
dial infarction (K75), heart failure and heart diseases
(K77, K84, K99), chronic obstructive pulmonary diseases,
asthma (R79, R95, R96), and urological conditions (U14,
U88, Y85, U78, Y79). Also, patients discontinued or
switched their drug prescription before fasting glucose
was measured, or prescribed at least one oral hypoglyc-
emic agents or insulin preparations during the study
period were excluded from the analysis.
Each patient was classified into one drug group according
to the antihypertensive drug class prescribed. These
include BBs, thiazide diuretics, Calcium Channel Blockers
(CCBs), drugs acting on the rennin angiotensin systemBMC Clinical Pharmacology 2008, 8:6 http://www.biomedcentral.com/1472-6904/8/6
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(RAS) and others (including α-blockers, potassium-spar-
ing diuretics, vasodilators and combination therapy).
Outcomes and Covariates
The proportions of patients having desirable (≤ 6.0
mmol/l), borderline (6.1–6.9 mmol/l) and adverse (≥ 7.0
mmol/l) levels of fasting glucose levels were compared
among the various drug classes. Plasma glucose from
blood collected after an overnight fast of 8 to 12 hours was
assayed enzymatically with commercial reagents (Abbott
Laboratory Limited). Independent predictors and covari-
ates of elevated fasting glucose levels include patient age,
gender, patients' payment status (fee waivers vs. payers;
each consultation costs US$5.77 including prescription
and investigation fees), district of residence, type of clinics
attended, namely General Out Patient Clinics (GOPCs),
Family Medicine Specialist Clinics (FMSCs) and Staff
Clinics (SCs), and the antihypertensive drug classes pre-
scribed (thiazide diuretics, BB, CCB, RAS).
Statistical Analysis
All the data were entered into the Statistical Package for
Social Sciences (SPSS) version 13.0. A descriptive analysis
was performed and the proportions of patients having
desirable, borderline and adverse lipid results were com-
pared by χ2 tests of homogeneity. Student's t-tests were
used to compare continuous variables, except the time
periods from antihypertensive prescription to blood
measurement where Kruskal Wallis test was used for the
skewed distribution. The crude odds ratios of each drug
class having above borderline (≥ 6.1 mmol/l) and adverse
(≥ 7.0 mmol/l) glucose readings were examined respec-
tively using bivariate analysis. This is followed by two sep-
arate unconditional binary logistic regression analyses for
above borderline and adverse glucose readings using all
the potential associated factors and covariates as inde-
pendent variables. The enter method was adopted as the
regression selection procedure, and drug classes included
thiazide diuretics, BB and CCB with RAS as a reference
group. All p values were two-sided, and p < 0.05 were
regarded as statistically significant.
Results
Patient characteristics
There were 1,218 eligible patients (Table 1). Overall the
mean age was 60.39 years (95% C.I. 59.67, 61.11 years),
Table 1: Patient characteristics (N = 1,218)
β-blockers 
(n = 307)
Thiazide 
(n = 196)
CCBs 
(n = 322)
RAS 
(n = 55)
Others* 
(n = 338)
p value
Age (years)
<50 85 (27.7) 38 (19.4) 74 (23.0) 9 (16.4) 58 (17.2) <0.001
50–59 113 (36.8) 62 (31.6) 87 (27.0) 22 (40.0) 84 (24.9)
60–69 59 (19.2) 51 (26.0) 70 (21.7) 11 (20.0) 77 (22.8)
≥ 70 50 (16.3) 45 (23.0) 91 (28.3) 13 (23.6) 119 (35.2)
Mean Age 56.96 60.14 60.80 60.02 63.30 <0.001
(SD) (11.67) (11.37) (13.21) (12.83) (13.42)
(95% CI) (55.651,58.27) (58.54, 61.74) (59.36, 62.25) (56.55, 63.49) (61.87, 64.74)
Gender (no./%)
Female 200 (65.1) 124 (63.3) 168 (52.2) 33 (60.0) 189 (55.9) 0.008
Male 107 (34.9) 72 (36.7) 154 (47.8) 22 (40.0) 149 (44.1)
Payment
Fee-waivers 107 (34.9) 68 (34.7) 107 (33.2) 17 (30.9) 96 (28.4) 0.415
Payers 200 (65.1) 128 (65.3) 215 (66.8) 38 (69.1) 242 (71.6)
District of residence
Shatin 85 (27.7) 44 (22.4) 84 (26.1) 12 (21.8) 135 (39.9) <0.001
Taipo 31 (10.1) 13 (6.6) 52 (16.1) 5 (9.1) 37 (10.9)
Northern 161 (52.8) 127 (64.8) 169 (52.5) 34 (61.8) 134 (39.6)
Others 30 (9.4) 12 (6.1) 17 (5.3) 4 (7.3) 32 (9.5)
Service type
General 264 (86.0) 179 (91.3) 288 (89.4) 48 (87.3) 275 (81.4) <0.001
FMSC 29 (9.4) 7 (3.6) 27 (8.4) 4 (7.3) 56 (16.6)
Staff clinic 14 (4.6) 10 (5.1) 7 (2.2) 3 (5.5) 7 (2.1)
Glucose Profile 5.42 5.48 5.46 5.41 5.60 0.786
(mean ± 95% CI) (5.34, 5.51) (5.38, 5.59) (5.37, 5.54) (5.20, 5.61) (5.52, 5.68)
Period from drug prescription to blood taking (weeks) 7.43 7.00 7.79 6.71 8.00 0.054**
Median (IQR) (5.86, 10.00) (5.18, 8.96) (5.57, 10.32) (5.00, 10.00) (6.00, 12.00)
(CCB: Calcium channel blockers; RAS: drugs acting on the rennin angiotensin system, IQR: Inter-quartile Ranges)
*Others refer to drug classes including α-blockers, polytherapy, combination therapy, and Misc classes
**Refers to comparison among four drug groups: β-blockers, thiazide diuretics, CCB, RAS)BMC Clinical Pharmacology 2008, 8:6 http://www.biomedcentral.com/1472-6904/8/6
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with females comprising 58.6% of the sample. The median
period between the first-ever antihypertensive drug pre-
scription and checking of fasting glucose was 7 weeks and
these periods were statistically similar among all the drug
groups (p = 0.054) (Table 1). The average age of patients
varied significantly across different drug groups (p <
0.001), thought the size of the differences were relatively
small (Table 1). Gender differences according to the type
of drug prescribed were also evident (p = 0.008). Socio-
economic status (with payment status as a proxy measure)
of patients did not vary significantly across drug classes (p
= 0.415). Most of them lived in more rural areas (29.6%,
11.3%, 51.3% and 7.8% living in Shatin, Taipo, North dis-
trict and other regions respectively), a finding which
reflects that less affluent regions have higher proportion of
patients suffering from uncomplicated hypertension only
as the single disease entity without other clustering of car-
diovascular (CVS) factors. The most frequently attended
clinics were GOPCs (86.5%), followed by FMSCs (10.1%)
and staff clinics (3.4%), statistically different across antihy-
pertensive drug classes (p < 0.001).
Patterns of fasting glucose profiles by antihypertensive 
drug group
Among the four major antihypertensive drug classes, the
mean glucose level was 5.45 mmol/l (95% C.I. 5.41,
5.49). Thiazide users had the highest absolute levels of
fasting glucose (5.48 mmol/l), followed by CCB (5.46
mmol/l), BB (5.42 mmol/l) and RAS (5.41 mmol/l).
However these apparent differences in glucose parameters
between drug groups were all statistically insignificant (p
= 0.786) (Table 1).
The overall proportions of patients having desirable, bor-
derline and adverse fasting glucose were 83.2%, 13.6%,
and 3.2% respectively (Table 2). Among the four drug
classes, the proportions of patients having borderline or
adverse fasting glucose levels were highest among RAS
users (16.0%), followed by BB (15.7%), thiazide diuretics
(15.0%) and CCB (13.0%) (Table 2), but these differences
were statistically insignificant (p = 0.849).
Factors associated with impaired fasting glucose
From bivariate analysis between drug class prescribed and
the likelihood of patients having adverse fasting glucose
readings, CCB users were significantly less likely to
present with above borderline fasting glucose (OR 0.604,
95% C.I. 0.390, 0.933, p = 0.022) when compared with
other drug classes (Table 3). Otherwise all other compari-
sons among the four drug classes were statistically similar
(p = 0.278 to 0.986). However, after controlling for con-
founding variables by means of multivariate logistic
regression, all drug classes were statistically similar in pre-
senting with above borderline (p = 0.549 to 0.819) and
adverse (p = 0.334 to 0.441) glucose readings.
When compared to young age (<50 years), older patients
≥ 70 years were 2.103 times (95% C.I. 1.051, 4.207, p =
0.036) more likely to present with above borderline glu-
cose levels (Table 4). Age was not significantly associated
with adverse glucose readings. While female patients were
similarly likely to have above borderline glucose readings
when compared with male patients (p = 0.102), they were
significantly less likely to have adverse readings (OR
0.223, 95% C.I. 0.074, 0.674, p = 0.008). Payment status
was not significantly associated with above borderline
and adverse glucose levels. Patients living in the North
district, a region with the lowest income level among all
districts, were significantly less likely to have adverse glu-
cose levels (OR 0.311, 95% C.I. 0.115, 0.841, p = 0.021)
than residents in Shatin.
Patients attending different types of clinics were found to
have similar odds of having above borderline (p = 0.179
to 0.414) and adverse fasting glucose levels (p = 0.266 to
0.668) (Table 4).
Discussion
Major Findings
In the present study, we examined the factors associated
with impaired fasting glucose among Chinese hyperten-
sive patients prescribed a single antihypertensive agent.
No significant associations were found between antihy-
pertensive drug class and different extents of impaired
fasting glucose. Elderly patients (≥ 70 years) were more
likely to have above borderline fasting glucose levels
while female patients were less likely to have adverse glu-
cose readings. Patients residing in rural areas were less
likely to present with adverse glucose readings.
Table 2: Patterns of glucose profiles by drug group (No./%)
β-blockers Thiazide CCBs RAS Others P (χ2)
Glucose (mmol/l) (n = 280) (n = 180) (n = 291) (n = 50) (n = 296)
Desirable (≤ 6.0) 236 (84.3) 153 (85.0) 253 (86.9) 42 (84.0) 229 (77.4) 0.849
Borderline (6.1–6.9) 35 (12.5) 22 (12.2) 28 (9.6) 5 (10.0) 59 (19.9)
Adverse (≥ 7.0) 9 (3.2) 5 (2.8) 10 (3.4) 3 (6.0) 8 (2.7)
(CCB: Calcium channel blockers; RAS: drugs acting on the rennin angiotensin system.
Glucose levels for desirable: ≤ 6.0 mmol/l, borderline: 6.1–6.9 mmol/l; adverse: ≥ 7.0 mmol/l)BMC Clinical Pharmacology 2008, 8:6 http://www.biomedcentral.com/1472-6904/8/6
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Interpretations of findings and relationship to published 
literature
Thiazide diuretics could increase insulin resistance [18],
affect glucose utilization [2], precipitate overt diabetes
[10] and worsen diabetes control [19] but the average rise
in blood glucose levels in long term resistance trials in
diuretic-treated patients was small compared with pla-
cebo subjects. Also in large prospective trials unfavorable
clinical outcomes have not been reported, and the
increase in cumulative incidence of new-onset diabetes is
by approximately 0.6% only [20-25].
From the ALLHAT study a small increase in serum glucose
and a minor rise (3.5%) in the absolute risk of developing
new-onset diabetes was reported in the thiazide group
(11.6%) versus lisinopril (8.1%), but the frequency of
CVS events was found to be similar between the two drug
classes in a five year period [26]. This finding is in echo
with the results from the Controlled Onset Verapamil
Investigation of Cardiovascular End Points (CONVINCE)
trial where diabetic cohorts receiving verapamil, thiazides
Table 3: The crude hazard ratios of having above borderline and adverse glucose profiles for each antihypertensive drug group
Bivariate Analysis Crude Odds Ratios for above 
borderline results (95% C.I.) (≥ 6.1 mmol/l)
p value Bivariate Analysis Crude Odds Ratios for 
adverse results (95% C.I.) (≥ 7.0 mmol/l)
p value
(1). β-blockers 0.881 (0.586, 1.323) 0.540 0.993 (0.459, 2.150) 0.986
(2). Thiazide Diuretics 0.860 (0.530, 1.397) 0.543 0.828 (0.316, 2.168) 0.700
(3). CCB 0.604 (0.390, 0.933) 0.022 1.043 (0.494, 2.204) 0.911
(4). RAS 0.720 (0.280, 1.850) 0.493 1.944 (0.572, 6.607) 0.278
(CCB: Calcium channel blockers; RAS: drugs acting on the rennin angiotensin system. Glucose levels for desirable: ≤ 6.0 mmol/l, above borderline: 
≥ 6.1 mmol/l; adverse: ≥ 7.0 mmol/l. The desirable group was used as the reference)
Table 4: Factors associated with hyperglycemia with above borderline and adverse readings*
Above Borderline readings Adverse readings
Odds Ratios (95% CI) p Odds Ratios (95% CI) p
Age (years)
<50 1.0 (ref) 1.0 (ref)
50–59 1.249 (0.648, 2.408) 0.506 1.776 (0.533, 5.919) 0.349
60–69 1.344 (0.654, 2.759) 0.421 0.784 (0.167, 3.685) 0.758
≥ 70 2.103 (1.051, 4.207) 0.036 1.359 (0.372, 4.962) 0.643
Gender
Male 1.0 (ref) 1.0 (ref)
Female 1.464 (0.927, 2.313) 0.102 0.223 (0.074, 0.674) 0.008
Payment status
Fee waiver 1.0 (ref) 1.0 (ref)
Fee payers 1.328 (0.789, 2.236) 0.286 0.759 (0.320, 1.798) 0.530
District of residence
Shatin 1.0 (ref) 1.0 (ref)
Taipo 0.967 (0.433, 2.156) 0.934 1.676 (0.588, 4.778) 0.334
North 0.707 (0.392, 1.273) 0.248 0.311 (0.115, 0.841) 0.021
Others 0.909 (0.363, 2.279) 0.839 N/A N/A
Clinics
GOPC 1.0 (ref)
FMSC 0.652 (0.234, 1.818) 0.414 0.299 (0.036, 2.507) 0.266
Staff clinics 2.071 (0.717, 5.984) 0.179 0.614 (0.066, 5.732) 0.668
Drug class
RAS 1.0 (ref) 1.0 (ref)
β-blockers 1.360 (0.497, 3.721) 0.549 0.518 (0.125, 2.151) 0.365
Thiazide 1.252 (0.443, 3.537) 0.672 0.466 (0.099, 2.190) 0.334
CCB 0.888 (0.320, 2.463) 0.819 0.575 (0.140, 2.353) 0.441
(C.I: confidence intervals, GOPC: General Out-patient clinics, FMSC: Family Medicine Specialist Clinics. RAS: drugs acting on the renin angiotensin 
system; CCB: Calcium channel blockers.
*Above borderline readings were defined as fasting glucose ≥ 6.1 mmol/l; adverse readings as fasting glucose ≥ 7.0 mmol/l. All adjusted Odds Ratio 
were adjusted for age, gender, payment status, district of residence, service types of attended clinics and other drug classes as listed in table
N/A: No patients presented with adverse readings)BMC Clinical Pharmacology 2008, 8:6 http://www.biomedcentral.com/1472-6904/8/6
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or β-blockers had similar CVS outcomes [27]. In addition,
in a large prospective cohort study of 12,500 hypertensive
patients [28] no increase in the incidence of diabetes was
noted with therapeutically low doses equivalent to 12.5
mg of hydrochlorothiazide.
Another notable finding from ALLHAT revealed that dia-
betic subjects who received thiazide diuretics had coro-
nary heart disease outcomes equal to diabetic subjects
who received ACEIs (namely lisinopril or amlodipine),
yet suffered from fewer strokes or episodes of heart failure
than the lisinopril group. In both diabetic and non-dia-
betic cohorts, less incidence of heart failure was reported
among patients treated with thiazide diuretics than with
amlodipine [26]. The observation that thiazide use in dia-
betic patients could be favorable is also supported by the
majority of studies where diabetic patients had fewer CVS
outcomes than non-diabetic patients when both groups
were prescribed thiazides [29]. Also patients receiving a
thiazide (chlorthalidone) in the SHEP trial, although hav-
ing an increased incidence of diabetes, did not have a
higher rate of CVS events after an average of 14.3 years fol-
low-up [30].
However, it should be noted that current literatures are
still mixed in the opinions of using thiazides in diabetic
patients, where "future troubles should be recognized"
[31] particularly in newly diagnosed diabetic patients who
may have increased risk of heart attack [32]. Although
studies have demonstrated superior efficacy of drugs act-
ing on RAS in preventing new-onset type 2 diabetes,
namely captopril [33], ramipril [34] and losartan [35],
thaizides were found to be necessary to reach blood pres-
sure goals in diabetic patients. The protective effect of RAS
on occurrence of diabetes has been postulated to be potas-
sium elevation which has been recognized to play a cru-
cial role in preventing diabetes [36,37]. Combined use of
RAS and thiazide diuretics have been recommended in
hypertensive patients with family history of diabetes or
components of metabolic syndrome like obesity, espe-
cially in patients with stage 2 hypertension [2].
The present study has reported no association of antihy-
pertensive drug class with any degrees of impaired fasting
glucose, and is therefore compatible with evidence favor-
ing the use of thiazide diuretics in uncomplicated hyper-
tension applicable also to ethnic Chinese patients.
It was well recognized that ageing is associated with
impaired beta cell repair, insulin resistance and hence
impaired fasting glucose [38] which is consistent with our
study findings reporting ageing as positively associated
with above borderline glucose levels. The relative risks of
diabetes for women have been higher than men in all ages
[39], and women were also more likely to have abnormal
glucose regulation [40]. The present study, on the con-
trary, demonstrated that female is at lower risk of having
adverse glucose readings.
Hyperglycaemia is a concentration-dependent predictor
of long-term mortality after a coronary event, and this pre-
dictive value is stronger in men than women [41]. But risk
of coronary heart disease in women may be elevated at a
lower glucose level than for men [42], consistent with
other findings that diabetes was reported as a greater risk
factor for cardiovascular diseases in women than in men
[43,44]. Therefore in the present study, the lower odds of
having impaired fasting glucose in women than men
should be interpreted in the light of the greater risk of inci-
dence of CVS diseases among diabetic women than dia-
betic men.
Patients residing in more rural areas, namely the North
district, may have more healthy dietary lifestyles. No stud-
ies have evaluated the association between socioeco-
nomic status and elevated fasting glucose, and this area
remains to be explored.
Strengths and weaknesses of current study
The present study adopted an observational design
including only antihypertensive drug naïve patients newly
received an antihypertensive agent without oral hypoglyc-
emic agents or insulin use, concomitant cardiovascular
disorders or other medical conditions which could con-
found choice of prescriptions. The periods where glucose
levels were checked after the prescription were approxi-
mately 7 weeks which were statistically similar among the
four drug groups. In conjunction with our fairly large sam-
ple size we believed this study reflects real-world clinical
practice. Also our patients had similar sociodemographic
characteristics compared to the entire population of Hong
Kong [21] making it more likely that our findings are gen-
eralizable.
However, some limitations of this study should be dis-
cussed. First, we do not have a baseline glucose profile
which could act as reference levels for comparisons of lev-
els before and after drug prescriptions, and this study only
evaluated a short time frame of approximately seven
weeks, a period which might not suffice metabolic effects
to take place. Also, we regarded the absence of ICPC cod-
ing as meaning the absence of the relevant condition, but
in a previous validation study of this clinical database [16]
it was shown that patients coded with K86 (uncompli-
cated hypertension) only were likely to be suffering from
uncomplicated hypertension as the single disease entity
without other concomitant medical conditions. In addi-
tion, age, gender and district of residence were associatedBMC Clinical Pharmacology 2008, 8:6 http://www.biomedcentral.com/1472-6904/8/6
Page 7 of 8
(page number not for citation purposes)
with either above borderline or adverse glucose readings
(but not both), which might weaken the conclusion
drawn. Some confounders like smoking and risk factors
for developing impaired glucose tolerance like obesity
could not be controlled for due to lack of relevant data,
and the absence of oral glucose tolerance tests would
mean the diagnosis of impaired glucose tolerance could
not be ascertained. Finally, our study cannot prove causa-
tive relationships between the predictor variables and glu-
cose profiles, which could only be addressed by a
prospective cohort design.
Implications for policy and practice
This study evaluated age, gender, socioeconomic factors,
types of clinic services and the antihypertensive drug
classes as associated factors of impaired fasting glucose in
Chinese patients with uncomplicated hypertension. Phy-
sicians may practice higher caution in managing hyper-
tensive patients with these associated factors at higher risk
of impaired fasting glucose, implying a greater need for
more regular screening of glucose profiles, especially
among older patients, males, and those residing in more
urbanized areas. The antihypertensive drug classes were
not shown to be associated with impaired glucose levels,
nor were they associated with drug discontinuation
[45,46], switching [46] or dyslipidemia [47] as reported in
previous studies. The use of thiazide as a first-line agent in
patients with uncomplicated hypertension could be justi-
fied in ethnic Chinese according to recommendations
from most international guidelines.
Conclusion
We examined the independent factors associated with the
presentation of impaired fasting glucose among 1,218
hypertensive patients newly prescribed a single antihyper-
tensive agent. Age, gender and district of residence were
significant independent predictors of impaired fasting
glucose among Chinese hypertensive patients while anti-
hypertensive drug classes were not associated with ele-
vated glucose readings. Physicians could use these
independent factors as a reference for more meticulous
monitoring of glucose levels among hypertensive Chinese
patients presented with these associated factors.
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